Key facts
- It has raised $490K; the latest was Later Stage VC ($490K) in Apr 2026.
- Status: Acquired/Merged (Operating Subsidiary).
- ·Watchlist + deal alerts for Vasonoxol
- ·The full record, as it builds
Funding rounds
No funding rounds for Vasonoxol are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Vasonoxol
Manufacturer of a nitric oxide supplement intended to promote blood circulation and cardiovascular health. The company's supplements are aimed at individuals seeking natural ways to support blood flow and potentially improve overall heart health, combines natural ingredients such as L-Arginine, L-Citrulline, and Red Yeast Rice to promote healthy blood flow and nitric oxide production, enabling consumers to care for their health.
- Sector
- Healthcare
- HQ
- Alexandria, VA, United States
- Founded
- 2011
- Employees
- 24
- Website
- vasonoxol.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Vasonoxol doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vasonoxol shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vasonoxol in its N-PORT filings yet. We sweep new filings monthly.